Organization | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology

Belarusian Research Center for Pediatric Oncology, Hematology and Immunology Report issue

Academic/Hospital Phase 1 Phase 2

Founded: Minsk Belarus (1997)

Organization Overview

First Clinical Trial

2018

NCT04434794

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Alternative names

Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | Belarussian Research Center for Pediatric Oncology, Hematology and Immunology | Head of the Department of Prosthodontics of BMAPE

Active Ingredients

Drugs in Phase 2 Trials (2)

autologous mesenchymal cells (1 trial)

autologous mesenchymal stem cells (1 trial)

Drugs in Phase 1 Trials (5)

aldesleukin (proleukin) (1 trial)

conjugate of plasmid dna with linear polyethylenimine 20 kda (pei) (1 trial)

haploidentical natural killer cell (1 trial)

lenalidomide (revlimid) (1 trial)

ss2017 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acute Disease (Phase 1)

Chronic Periodontitis (Phase 2)

Gingival Recession (Phase 2)

Leukemia (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Neuroblastoma (Phase 1)

Periodontitis (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 4
# of Trial APIs: 7